Each material 8-K filed by an S&P 1500 company, read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (1506 companies, A–Z).
UFP Industries filed an investor relations presentation under Regulation FD, posted to its investor website, with results through September 26, 2026. The Q3 2026 figures show net sales up from the prior-year quarter while adjusted EBITDA declined, and the presentation reiterates a $198 million share repurchase authorization remaining as of October 28, 2026.
Q3 2026 net sales were $1,733 million, compared with $1,560 million in Q3 2025.
Q3 2026 adjusted EBITDA was $119 million, compared with $140 million in Q3 2025.
Trailing twelve-month net sales were $6.4 billion and adjusted EBITDA was $492.3 million as of Q3 2026.
Share repurchase authorization had $198 million remaining as of October 28, 2026, and expires April 30, 2027.
Atlantic Union Bankshares furnished an investor presentation under Regulation FD for meetings with investors and analysts in the fourth quarter of 2026. The deck reports Q3 2026 adjusted operating diluted EPS of $0.96, and several 2026 outlook items are described as at the low end of their ranges. For shareholders, the reported tangible book value per share fell from $20.77 to $20.36 in the quarter, mainly because of AOCI, while the company repurchased $62.5 million of common stock.
Q3 2026 adjusted operating diluted EPS of $0.96; adjusted operating ROTCE of 19.85% and ROA of 1.45%
2026 outlook: loans $29.0-30.0 billion and deposits $31.0-32.0 billion; net interest income, net interest margin, noninterest income and expense all described as low end of range
Reported tangible book value per share was $20.36 at September 30, 2026, down from $20.77 at June 30, 2026; $23.22 excluding AOCI
Q3 2026 dividend of 37 cents per share, up 8.8% from the third quarter of 2025; $62.5 million of common stock repurchased at an average price of $41.38
Xencor said its current operating plans give it cash to fund research, development and operations into 2029. The company also released updated Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, reporting confirmed objective response rates of 30.0% to 45.5% across three dose levels. The data are early and come from small groups, and the filing reports high rates of grade 3 or higher adverse events.
Cash expected to fund R&D and operations into 2029, based on current operating plans.
Confirmed objective response rate: 30.0% at 100 μg/kg (n=30), 44.0% at 200 μg/kg (n=25), 45.5% at 400 μg/kg (n=11).
Grade 3 or higher treatment-emergent adverse events occurred in 82.4% of expansion-dose patients (n=68); one treatment discontinuation due to cytokine release syndrome was reported.
Full 400 μg/kg analysis expected during 1H 2027 (20+ patients); a potential registration-enabling study is planned to start in 2027.
American Express furnished preliminary delinquency and write-off statistics for its U.S. Consumer and U.S. Small Business Card balances held for investment through September 30, 2026. Consumer and small business net write-off rates were lower in September than in July and August, while 30-day delinquency rates rose slightly, so the monthly credit picture is mixed for shareholders.
U.S. Consumer Card net write-off rate (principal only) was 1.5% in September, down from 1.7% in both August and July.
U.S. Consumer 30-day past due rate was 1.2% in September, up from 1.1% in August and July.
U.S. Small Business 30-day past due rate was 1.4% in September, up from 1.3% in August and July; its net write-off rate was 2.1%, down from 2.2% in August and 2.6% in July.
Total Card balances held for investment were $160.9 billion at September 30, 2026, up from $160.3 billion at August 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by S&P 500, MidCap 400 and SmallCap 600 companies that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
The SEC filing feed is checked every hour on weekdays between 7 am and 9 pm Eastern; briefs follow within that hour or, when many filings arrive at once, later the same day.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.